Ewelina Rogala

Medical University of Lublin, Lyublin, Lublin Voivodeship, Poland

Are you Ewelina Rogala?

Claim your profile

Publications (11)24.51 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Tumor progression is associated with the function of the immune system. Recent studies have shown that indoleamine 2,3-dioxygenase (IDO) is one of the molecules involved in tumor-induced immunosuppression. IDO probably induces tumor progression through inhibiting NK cells and T lymphocytes activity. Aim of the study: The aim of our study was to assess indoleamine 2,3-dioxygenase at the mRNA level in ovarian serous and endometrial adenocarcinoma. Material and methods: Forty patients (15 before and 25 after menopause) operated due to advanced ovarian carcinoma were recruited. mRNA expression of IDO was assessed by means of real-time PCR. The control group was represented by normal ovary tissue. Results: Indoleamine 2,3-dioxygenase was expressed at the mRNA level in all ovarian cancer patients. It was significantly higher (p < 0.005) in cancer tissue than in healthy controls (RQ = 0.040). The expression of IDO in serous ovarian cancer (RQ = 0.319) was significantly higher (p = 0.02) compared with the expression in endometrioid cancer (RQ = 0.091). The expression of IDO in ovarian cancer patients with clinical stage III was higher than in patients with clinical stage II, but this difference did not reach statistical significance. There was no statistically important difference between the expression of IDO in ovarian cancer patients in relation to grading and menopausal status. Conclusions: IDO positive expression is different among the histological types.
    No preview · Article · Jun 2013 · Menopausal Review
  • [Show abstract] [Hide abstract]
    ABSTRACT: Conservative treatment of metastatic germ-cell tumor of the ovary does not exclude the possibility of pregnancy in the future. Serum beta-human chorionic gonadotropin (beta-hCG) serves as pregnancy test, and has also been proven to be a useful marker for ovarian germ-cell tumors. This paper is a case report of a 19-year-old patient who was admitted to a district hospital in emergency due to pelvic pain, amenorrhoea, and free fluid in the pelvis. Laboratory tests demonstrated slight increase in beta-hCG serum concentration and transvaginal ultrasound (TVUS) showed no evidence of gestational sac in the uterus. At the age of 14, the patient was diagnosed with malignant germ-cell tumor of the left ovary in FIGO Stage IV and was treated with four courses of chemotherapy according to TGM-95 protocol with etoposide, ifosfamide, and cisplatin, followed by conservative surgery and adjuvant two courses of cytostatics. The initial diagnosis was recurrence of ovarian malignancy and the patient was referred to an oncology center. Wait-and-see approach and repeated ultrasound examination confirmed a normal intrauterine pregnancy which concluded with the delivery of a healthy newborn through cesarean section.
    No preview · Article · Jan 2013 · European journal of gynaecological oncology
  • [Show abstract] [Hide abstract]
    ABSTRACT: The process of T cells activation is necessary for the performance of the defense functions. Successful activation depends on direct lymphocyte - antigen-presenting cell contact and signal transmission to the lymphocyte. Activated T cells exhibit surface expression of molecules such as CD69, CD25 and HLA-DR. The effect of cell activation is a cascade of molecular events leading to proliferation and clonal expansion of antigen-specific T cells. The aim of this study was to evaluate the phenotype and T cell activation markers: CD69, CD25 and HLA - DR in the peripheral blood and tumor tissue of ovarian cancer patients. Material and methods: The study group consisted of 26 patients operated due to ovarian cancer (FIGO Ilb - IV). Mononuclear immune cells were isolated from peripheral blood and ovarian cancer tissue. To obtain peripheral blood lymphocytes, blood was collected into heparinized tubes and diluted 1:1 with PBS, then layered on Gradisol L and centrifuged 20 minutes at 2800 rpm. Mononuclear cells were washed twice with PBS and labeled with monoclonal antibodies. A small piece of tumor tissue (about 1cm3) was fragmented with a surgical blade. Minced tissue was suspended in PBS and layered on Gradisol L for mononuclear cells isolation. To assess the phenotype and activation status of peripheral blood and tumor infiltrating lymphocytes, we used FACS Canto cytometer and monoclonal antibodies conjugated with fluorochromes: anti-CD3-FITC, anti-CD4-PE-Cy5, anti-CD8-APC, anti-CD25-PE, anti-CD69-PE-Cy7, anti-HLA-DR-PE-Cy7. Statistical analysis was performed using the Statistica 5.0 and Wilcoxon test. In all cases we detected T helper CD3+CD4+ and cytotoxic CD3+CD8+. T lymphocytes in both blood samples and tumor tissues. We observed no statistically significant difference in the percentage of CD3+ CD4+ cells among the mononuclear cells present in peripheral blood and tumor tissue. The percentage of CD3+CD8+ cytotoxic T lymphocytes was higher among mononuclear cells isolated from the tumor tissue. The percentage of CD3+ lymphocytes expressing the very early activation marker CD69 was significantly higher among tumor infiltrating lymphocytes compared with peripheral blood lymphocytes. Similarly the percentages of CD3+CD4+CD69+ T helper lymphocytes and CD3+CD8+CD69+ cytotoxic T lymphocytes were significantly higher on lymphocytes isolated from tumor tissue when compared to blood. The expression of an early activation marker - CD25 was significantly higher on the CD3+ and CD3+CD8+ peripheral blood lymphocytes compared to CD3+ and CD3+CD8+ tumor infiltrating lymphocytes. There were no statistically important differences between the percentages of, isolated from blood and tissue, CD3+CD4+ T helper lymphocytes. The expression of the late activation marker - HLA-DR was significantly higher on CD3+ lymphocytes isolated from tumor tissue compared with peripheral blood. Similarly the percentages of CD3+CD4+ lymphocytes and CD3+CD8+ cytotoxic T cells expressing HLA-DR were significantly higher among tumor infiltrating lymphocytes when compared to peripheral blood ones. T cells obtained from ovarian cancer tissues are activated cells. The state of T cell activation may be the result of direct contact of these cells with tumor antigens. The low expression of CD25 may suggest abnormal clonal expansion of antigen-specific lymphocytes.
    No preview · Article · Oct 2012 · Ginekologia polska

  • No preview · Article · Jul 2012 · European Journal of Cancer

  • No preview · Article · Jul 2012 · European Journal of Cancer

  • No preview · Article · Jul 2012 · European Journal of Cancer
  • [Show abstract] [Hide abstract]
    ABSTRACT: Knowledge of the role of interleukin 17 (IL-17) has led to the identification of new subpopulation of T helper lymphocytes--Th17 and T cytotoxic lymphocytes secreting IL-17 (Tc17). An increasing amount of attention is paid to their role in anti-tumor immunity. The aim of this study was to evaluate the percentage of peripheral blood, peritoneal fluid and cancer tissue CD4+ and CD8+ T lymphocytes producing IL-17 in patients with ovarian cancer Forty patients operated due to advanced ovarian carcinoma and twenty-four patients with functional follicle ovarian cysts were recruited. Peripheral blood, peritoneal fluid and cancer tissue mononuclear cells from ovarian cancer patients were stimulated for 4 hours ex vivo with phorbol myristate acetate (PMA) (50 ng/ ml) and ionomycin (1 microg/ml). The percentage of CD4+ and CD8+ T cells producing IL-17 was measured using flow cytometry. CD4+ and CD8+ T lymphocytes producing IL-17 were detected in the peripheral blood, peritoneal fluid and cancer tissue of ovarian cancer patients. The percentage of CD4+ T cells producing IL-17 was higher in the peripheral blood, peritoneal fluid and cancer tissue when compared to CD8+/IL 17+ T cells. The percentage of CD4+/ IL-17+ was significantly higher in cancer tissue compared to T cells derived form peripheral blood. There was no difference in the percentage of CD4+/IL-17 + T cells between peripheral blood and peritoneal fluid and peritoneal fluid and cancer tissue of ovarian cancer patients. There was no difference in the percentage of CD8+/IL-17 + T lymphocytes in the peripheral blood, peritoneal fluid and cancer tissue in patients suffering from ovarian cancer. Increased percentage of CD4+/IL-17+ and CD8+/IL-17+ T cells in cancer tissue indicates that these cells are accumulated in ovarian cancer microenvironment.
    No preview · Article · Jun 2012 · Ginekologia polska
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Fast growing malignant tumors may use pathways alternative to endothelial angiogenesis vascularization pathways including vasculogenic mimicry (VM). Matrix metalloproteinases (MMPs) are important components of molecular switch to VM, but their possible contribution to VM formation in ovarian malignant tumors is not known. Aim of the study: Our goal was to examine the MMP-9 and VM expression in malignant and benign ovarian tumors. Material and methods: The study group comprised 67 women of whom 41 were postmenopausal. Mean age was 53.6 ±10.45 yrs (median 54 yrs, range: 23-86 yrs). Immunohistochemical MMP-9 expression with periodic acid-Schiff (PAS) staining for non-endothelial cell-lined blood vessels that were formed by tumor cells indicating vasculogenic mimicry were analyzed in all masses. There were 62 malignant tumors in the studied group. FIGO clinical stage and tumor histological grade (G1-G3) were compared with VM and MMP-9 expression assessed in serial histological preparations. Results: MMP-9 expression was found in 52 tumors (77.6%) and its strength (weak-medium-strong) was significantly correlated with the tumor histological type. Significant differences were found between benign tumors that had no or only a weak MMP-9 expression and malignant masses in which a medium or strong MMP-9 expression was found more frequently (26/45 cases of FIGO st. III tumors, Chi 2=13.1; p = 0.04). A high MMP-9 expression was found in 20% of primary ovarian cancer cases. No significant differences were found when malignant tumor histological grade or menopausal status of studied women were compared with MMP-9 expression (Chi 2 = 6.4; p = 0.37). PAS-positive structures indicating presence of VM were found in 30 (44.7%) ovarian cancers. MMP-9 was more frequently found in tumors with VM (Chi 2 = 15.8; p = 0.001). In 30 masses with PAS-positive structures, MMP-9 expression was more frequently high (11 cases) or medium (6 cases). All 37 masses without VM detected with PAS-positive reaction had a weak MMP-9 expression. Conclusions: Matrix metalloproteinase-9 appears to play an important role in the development of vasculogenic-like networks and matrix remodeling in a significant proportion of malignant ovarian tumors. Studies on the potential role of molecular factors controlling ovarian cancer vascularization pathways may be used in the future to develop new tumor angiogenesis blocking agents.
    No preview · Article · Apr 2012 · Menopausal Review
  • Iwona Wertel · Aldona Nowicka · Ewelina Rogala · Jan Kotarski
    [Show abstract] [Hide abstract]
    ABSTRACT: The development of epithelial ovarian cancer is associated with changes in the peritoneal cavity microenvironment. Tumor cells produce different factors, which impairs differentiation, maturation, and function of antigen-presenting cells. In this review, we focus on selected cell populations in the peritoneal cavity immune system and their potential role in epithelial ovarian cancer immunopathogenesis. We devote most attention to dendritic cells because they are considered to be superior in their antigen-presenting ability, compared with both macrophages and B lymphocytes. We also present a brief characterization of tumor-infiltraiting cells in epithelial ovarian cancer patients.
    No preview · Article · May 2011 · International Reviews Of Immunology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Proinflammatory and prooxidative environment in the peritoneal cavity may be involved in the pathogenesis of endometriosis. Imbalance between reactive oxygen species levels and the antioxidant capacity leads to oxidation of low-density lipoproteins (LDL). The importance of oxidized LDL (Ox-LDL) in the development of atherosclerosis is well recognized. The aim of our study was to evaluate for the presence of ox-LDL in the peritoneal fluid (PF) of women with and without endometriosis. A total of 60 women who underwent laparoscopy were divided into groups: endometriosis sufferers with minimal to mild (n 20) and moderate to severe (n 20) stages, and the reference group (n 20) with functional follicle ovarian cysts. Oxidized LDL levels were determined in the PF using enzyme immunoassay Oxidized LDL levels were detectable in all peritoneal fluid samples. Significantly increased levels of ox-LDL were observed in PF of women with stage III/IV endometriosis compared to the reference group (p = 0.03). However peritoneal fluid ox-LDL concentrations did not differ significantly between patients with minimal/mild and women with moderate/severe stage of the disease (p = 0.2). No significant difference in the PF ox-LDL concentrations was also found between women with stage I/II endometriosis and patients with follicle cysts (p = 0.3). Increased peritoneal fluid ox-LDL levels observed in women with advanced-stage endometriosis suggest the important role of oxidative stress in the pathogenesis of the disease.
    No preview · Article · Mar 2011 · Ginekologia polska
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of our study was to generate dendritic cells (DCs) from peripheral blood monocytes (PBMC) of patients suffering from ovarian cancer. Immature DCs were generated from PBMC cultured in RPMI 1640 medium with 2% human serum albumin (HSA), supplemented with recombinant human (rh) granulocyte macrophage colony stimulating factor (GM-CSF) and rh interleukin (IL)-4. After 5 days of culture, DC maturation was induced by the addition of an ovarian cancer cell line (CAOV3) lysate and after 6 days of rh tumor necrosis factor (TNF)-α for a further 2 days. The phenotype of the generated cells was assessed by flow cytometry for the expressions of human leukocyte antigen (HLA)-DR, costimulatory molecules (e.g., CD86, CD80), CD83, CD1a, and CD14. PBMC cultured in 2% HSA without rhIL-4, rhGM-CSF, rh-TNF-α, or tumor cell lysate formed the control group. The 2.41% (interquartile range, 1.51%-3.52%) of CD45+/CD14+ cells in cultures with rhIL-4, rhGM-CSF, rhTNF-α and tumor cell lysate was significantly lower than in the control group (31.10%; interquartile range, 11.11%-64.06%). Cultures with rhIL-4, rhGM-CSF, rhTNF-α, and tumor cell lysate showed a higher percentage (19.96%; interquartile range, 9.30%-24.42%) of fully mature CD83+/CD1a-/HLA-DR+ DCs compared with control culture (6.02%; interquartile range, 3.01%-7.37%). There was no significant difference in the expression of the immature DC marker (CD1a) between the cultures. The expression of co-stimulatory markers (CD80, CD86, HLA-DR) was greater (24.29%; interquartile range, 18.68%-33.95%) on DCs from cultures with rhIL-4, rhGM-CSF, TNF-α, and tumor cell lysate versus controls (4.93%; interquartile range, 2.67%-9.09%). Our data demonstrated that immature and mature DCs can be generated from adherent human PBMC from ovarian cancer patients cultured with rhIL-4, rhGM-CSF, rhTNF-α, and tumor cell lysates.
    No preview · Article · Oct 2010 · Transplantation Proceedings